All studies
CompletedPhase IIIInterventional

A study of the Ad26.COV2.S vaccine candidate for the prevention of SARS-CoV-2-mediated COVID-19 in adults

COVID-19 is a respiratory illness caused by the coronavirus SARS-CoV-2. It spreads easily and can lead to fever, a new cough, and severe chest infections, especially in older adults or people with ongoing health problems. This study tests an experimental vaccine, Ad26.COV2.S, to see how well it protects adults from COVID-19 and to check for any unwanted side effects. Adults aged 18 and older can take part. Half the participants will receive the trial vaccine, while the other half will receive a harmless saltwater injection (a placebo). Each volunteer receives two injections, given around two months apart. Over the study, doctors will monitor participants using quick nasal swabs, blood samples, and a daily symptoms diary completed on a digital device. The trial aims to find out whether this vaccine can safely stop people from becoming unwell.

At a glance

Status
Completed
Phase
Phase III
Sponsor
Janssen (Netherlands)
Enrolment target
30,000
Start
15 Nov 2020
Estimated completion
12 Mar 2021

What is this study about?

COVID-19 is an infection that attacks the lungs and airways. While some people experience mild illness or no symptoms at all, others can develop severe breathing problems and pneumonia. Adults over 60 and those living with conditions like asthma or diabetes face a higher chance of becoming seriously ill. Because the virus spreads quickly between people, developing safe and reliable vaccines is a vital step in helping the body fight off the infection before it causes harm.

Vaccines work by training the body's natural immune system to recognise and fight a specific germ. The study vaccine, Ad26.COV2.S, is designed to teach your body how to defend itself against the coronavirus. In this trial, researchers want to see whether two doses of the vaccine can prevent people from catching COVID-19 or reduce how severe the illness is if they do catch it.

This is a Phase 3 clinical trial, which means the vaccine has already passed early safety checks in smaller groups of people. It is now being tested in thousands of volunteers across the UK and worldwide. Large studies like this are essential to confirm that the vaccine is both safe and effective before it can be approved for wider public use.

Key takeaways

  • Tests whether the Ad26.COV2.S vaccine candidate safely protects adults from COVID-19.
  • Involves two injections given roughly two months apart.
  • Half of the volunteers receive the study vaccine, and half receive a harmless dummy jab.
  • Open to adults aged 18 and older, including those with stable health conditions.
  • Requires tracking daily symptoms on a simple electronic device.

Who may be eligible?

This trial is open to adults aged 18 and older. Both healthy volunteers and people with stable long-term conditions (such as managed diabetes or heart disease) can take part. Women who could become pregnant must take regular pregnancy tests and use approved contraception during the trial, and volunteers must agree not to donate blood during the study.

You cannot join if you currently have a high temperature or a sudden illness, though you may be able to join later once you recover. People who have had severe allergic reactions to vaccines in the past, or who have already received a coronavirus vaccine, are also unable to take part. In addition, you must not have received any other routine vaccinations in the weeks immediately before joining.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. You are aged 18 or older.
  2. You have not previously received a coronavirus vaccine.
  3. You do not have a history of severe allergic reactions (anaphylaxis) to vaccines.
  4. You are willing to fill in a quick electronic diary every day.
  5. You agree not to donate blood or bone marrow during the trial.
  6. You are not currently unwell with a fever or acute illness.
Answer every question to see your result.

What does participation involve?

Taking part involves receiving two injections into your upper arm, given about two months apart. You will be randomly assigned to receive either the trial vaccine or a dummy jab (sterile saltwater) so researchers can fairly compare results. Neither you nor the study team will know which injection you received until the study ends. You will visit the clinic for health checks, blood tests, saliva tests, and gentle nose swabs. Between visits, you will use a smartphone or electronic device to answer short daily questions about how you feel. If you ever develop cold or flu-like symptoms, the team will give you extra support and tests. Travel and parking costs for clinic visits will be refunded, and the study will run for up to several years to monitor your long-term health.

Potential risks and benefits

Common side effects are generally mild to moderate and include soreness, redness, or swelling where you had the injection, as well as temporary headaches, tiredness, muscle aches, or a mild fever. There is a very small risk of an allergic reaction. Because the vaccine is still being tested, researchers cannot guarantee that it will protect you from COVID-19. However, taking part helps doctors understand how to protect communities from the virus in future. Your participation is entirely voluntary, and you can leave the trial at any point without it affecting your standard NHS care.

Locations (26)

  • Southampton General Hospital
    Approximate
    Southampton, England
  • Leicester Royal Infirmary
    Approximate
    Leicester, England
  • Cambridge University Hospitals NHS Foundation Trust
    City only
    Cambridge, England
  • Central Manchester University Hospitals NHS Foundation Trust
    City only
    Manchester, England
  • Brighton & Sussex University Hospitals NHS Trust
    City only
    Brighton, England
  • Newcastle upon Tyne Hospitals NHS Foundation Trust
    Unverified
    Newcastle upon Tyne, England
  • Royal Free Hospital
    Unverified
    Hampstead, England
  • Imperial College London and Imperial College Healthcare NHS Trust
    Unverified
    London, England
  • Guy's and St Thomas' Hospital
    Unverified
    London, England
  • Derriford Hospital
    Unverified
    Plymouth, England
  • Queen Elizabeth Hospital
    Unverified
    Birmingham, England
  • University Hospitals Bristol NHS Trust
    Unverified
    Bristol, England

Common questions

Can the trial vaccine give me COVID-19?

No. The trial vaccine does not contain the live coronavirus, so it cannot infect you with COVID-19.

Will I definitely receive the real vaccine?

Not necessarily. Half of the participants will receive the trial vaccine, while the other half receive a dummy saltwater injection (placebo) to help researchers compare the results fairly.

Does taking part cost anything?

No. All study vaccines, clinic visits, and medical tests are free, and reasonable travel and parking expenses will be reimbursed.

What happens if I feel unwell during the study?

You will record your symptoms in a daily electronic diary. If you develop signs of COVID-19, the medical team will contact you, guide you through testing, and closely monitor your health.

Can I leave the study if I change my mind?

Yes. You are free to withdraw from the trial at any time, for any reason, and your normal healthcare will not be affected.

How to find out more

Shola Ayeni

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.